Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects

Fig. 2

Visual predictive check of the AMG 403 population pharmokinetics (PK) model. A two-compartment model was fit simultaneously to individual AMG 403 PK data from healthy volunteers (HV) and patients with knee osteoarthritis (OA). The model parameter estimates were used to simulate 1000 trials for a visual predictive check. The predicted median PK (solid line) and 80 % prediction interval (shaded area) are shown with the observed individual concentrations (solid dot). Note the different x-axis scales for the single-dose and multiple-dose regimens. IV intravenous, SC subcutaneous

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us